Thalidomide metabolites and methods of use
AssigneeAuckland Uniservices Limited
InventorsLai-Ming Ching, Brian D. Palmer
Life of this patent
Estimating the term…
Abstract
The present invention concerns certain hydrolytic thalidomide metabolites, combinations thereof with other anti-neoplastic compounds and their use in the treatment of solid tumours.
Claims11
Composition comprising one or more hydrolytic thalidomide metabolites, wherein at least one said metabolite possesses anti-tumour activity, optionally in combination with a pharmaceutically acceptable carrier.
Composition comprising one or more hydrolytic thalidomide metabolites, wherein at least one said metabolite possesses anti-angiogenic and/or cytokine modulatory activity, optionally in combination with a pharmaceutically acceptable carrier.
Synergistic composition comprising one or more thalidomide metabolites, wherein at least one said metabolite possesses anti-tumour, anti-angiogenic, and/or cytokine modulatory activity, and at least one other anti-neoplastic compound, optionally in combination with a pharmaceutically acceptable carrier.
Method of treating a solid tumour in a subject comprising the administration to the subject requiring such treatment a first composition comprising one or more hydrolytic thalidomide metabolites, wherein at least one said metabolite possesses anti-tumour activity, and a second composition comprising at least one other anti-neoplastic compound.
Dependencies are inferred from the claim text.